Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nabeel Akhter

Vascular & Interventional Radiology Baltimore, MD Medical Doctor

NPI 1487847075 CMS profile 22168

22 S Greene St, Dept Of Radiology, Baltimore, MD 21201

Open in the dashboard

General payments

$14,342

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nabeel Akhter of Baltimore, MD is reported in the CMS Open Payments database as having received $14,342 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,038 11
2024 General $2,537 20
2023 General $3,012 18
2022 General $3,261 14
2021 General $2,620 3
2019 General $1,875 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nabeel Akhter
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Nabeel Akhter were reported at $1,038. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Nabeel Akhter Vascular & Interventional Radiology median Middle half National median
2019 $1,875 $422 $125–$1,555 $163
2020 $0 $200 $68–$652 $114
2021 $2,620 $280 $99–$866 $132
2022 $3,261 $433 $137–$1,497 $149
2023 $3,012 $506 $152–$2,019 $160
2024 $2,537 $556 $175–$1,930 $164
2025 $1,038 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $6,088 46 payments
  2. Penumbra, Inc. $3,940 13 payments
  3. Canon Medical Systems USA, Inc. $2,540 2 payments
  4. Biocompatibles, Inc. $981 4 payments
  5. AngioDynamics, Inc. $398 4 payments
  6. Intera Oncology, Inc $228 1 payment
  7. Bard Peripheral Vascular, Inc. $60 3 payments
  8. Becton, Dickinson and Company $43 1 payment
  9. Sirtex Medical Inc $30 1 payment
  10. Inari Medical, Inc. $20 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $6,576 26 payments
  2. Food and Beverage $5,267 50 payments
  3. Consulting Fee $2,500 1 payment
Products named General payments · program years 2019–2025
  1. TheraSphere Y90 Glass Microspheres 10 GBq $3,991 16 payments
  2. Indigo System $3,800 12 payments
  3. Vascular $2,500 1 payment
  4. THERASPHERE - BIO $949 2 payments
  5. OBSIDIO $899 5 payments
  6. General Therapies $779 6 payments
  7. INTERA $228 1 payment
  8. ALPHAVAC $188 2 payments
  9. RUBY Coil $140 1 payment
  10. EMBOLD Fibered $140 8 payments
  11. Other $666 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

67

Median for Interventional Radiology: 38

Drug cost

$526

Median for Interventional Radiology: $333

Branded share of claims

0%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 27 $381
Ondansetron Hcl Generic 25 $99
Hydromorphone Hcl Generic 15 $46

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 174 billing codes

Paid by Medicare

$111,680

Medicare's payments for the services billed

Medicare patients

1,187

Average age 72

Services billed

2,341

792 women, 395 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 33%
Depression 30%
Ischemic heart disease 28%
Chronic kidney disease 28%
Cancer 24%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record